Merck raised its 2026 sales outlook to $66.3 billion–$67.3 billion on August 4, 2026, after the pharmaceutical giant beat second-quarter revenue estimates and reported strong performance across oncology and animal health. The new guidance represents an increase from the company’s previous range of $65.8 billion to $67.0 billion.
Merck reported second-quarter worldwide sales of $16.6 billion, up 5 percent year-over-year and exceeding analyst expectations of $16.27 billion to $16.41 billion. The company delivered a non-GAAP earnings per share of $2.13 for the quarter, according to earnings call data.
The company’s growth was driven by continued strength in oncology, where Merck’s flagship cancer drug Keytruda recorded $16.40 billion in first-half 2026 sales, up 4.2 percent year-over-year. Keytruda’s portfolio expanded with the initial uptake of Keytruda QLEX, a new formulation approved during the quarter. Animal health also contributed significantly to the quarter’s performance, along with increasing contributions from new product launches.
Chief Executive Officer Rob Davis said the company was “confident in the ongoing execution of our strategy” following the quarter’s achievements and regulatory milestones, including FDA approval of Lipfendra, a new treatment in Merck’s oncology portfolio.
Merck’s guidance raise reflects broader momentum in the pharmaceutical industry during the second quarter of 2026. Pfizer raised its midpoint 2026 revenue guidance by $500 million in early August, citing strong demand for its non-Covid medicines, while Eli Lilly also raised its 2026 forecast following a robust second-quarter performance. When Pfizer raised guidance in August 2026, the company attributed the increase to strong execution across its portfolio, a pattern similar to Merck’s own earnings narrative.
Despite the revenue beat and guidance raise, Merck reported a GAAP net loss of $1.335 billion for the quarter, reflecting one-time charges related to an acquisition. The company also cut its full-year adjusted earnings guidance to $2.66 to $2.76 per share, down from a prior outlook of $5.04 to $5.16, to account for the impact of these charges. The earnings miss was offset by the strength of the revenue beat, which drove investor confidence in the company’s operational trajectory and ability to execute against its strategic pipeline initiatives.
The company’s pipeline transformation continues to position Merck for sustained growth beyond Keytruda, which faces patent expiration risks in the coming years. New launches and regulatory approvals announced during the quarter underscore management’s confidence in the company’s ability to replace revenue and maintain its competitive position in oncology and other therapeutic areas.
Sources
- Merck investor relations — Q2 2026 financial results, revenue of $16.6 billion, guidance raised to $66.3 billion–$67.3 billion
- CNBC — Merck raised full-year 2026 revenue guidance to $66.3 billion–$67.3 billion from $65.8 billion–$67.0 billion
- Reuters — Merck beat second-quarter estimates with $16.6 billion in sales, Keytruda strength, and adjusted EPS guidance cut to $2.66–$2.76
- Yahoo Finance — Merck Q2 revenue of $16.6 billion beat expectations of $16.27 billion, non-GAAP EPS of $2.13
- Tickeron — Q2 2026 sales of $16.6 billion exceeded $16.41 billion consensus, oncology and animal health growth drivers
- Business Wire / Pfizer — Pfizer raised 2026 revenue guidance by $500 million at midpoint to $60.5 billion–$62.5 billion in August 2026
- Yahoo Finance / Eli Lilly — Eli Lilly raised 2026 outlook after strong Q2 2026 performance
